{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:28:12Z","timestamp":1764502092571,"version":"3.46.0"},"reference-count":30,"publisher":"Practical Medicine Publishing House","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Oncohematology"],"abstract":"<jats:p>Aim.\u00a0To analyze the relationship between expression of aberrant CD45, CD19, CD56 markers on the plasma cells and clinical and laboratory findings and prognostically significant parameters in patients with multiple myeloma (MM).\r\nMethods.\u00a0This scientific research includes data on clinical investigation and immunophenotyping of bone marrow cells obtained from 64 MM patients treated in the N.N. Blokhin Russian Cancer Research Center over the period from 2004 to 2015. The three-color flow cytometry was performed using a direct immunofluorescence technique (CD38-PerCP, CD138-FITC monoclonal antibodies) and PE-conjugated monoclonal antibodies against CD45, CD19, and CD56.\r\nResults.\u00a0Comparison of average values of the total count of plasma cells, the number of plasmablasts, proplasmacyte and mature plasma cells (according to the myelogram) and comparison of these data with the level of expression of the CD19 marker demonstrated a significant relationship between the CD19 negative immunophenotype and both a higher level of the total count of plasma cells and immature plasma cells. There also was a significant correlation between the CD19 negative immunophenotype and a higher level of C-reactive protein, which is significant prognostic factor in MM. In addition, there was a significant relationship between the CD19 negative phenotype and a higher percentage of young neutrophils in blood, i.e. with a more frequent \u201cleft shift\u201d. The CD56 negative phenotype is associated with plasmablastic morphology of plasma cells and with the presence of plasma cells in the peripheral blood. Plasma cell leukemia is more common in patients with \u0421D56 negative phenotype of myeloma cells. The CD45 negative immunophenotype was associated with a higher level of k-type FLCs, Bence-Jones proteinuria and with a higher serum creatinine, than in the cases of CD45 positive phenotype.\r\nConclusion.\u00a0The study of the immunophenotype of plasma cells in MM has important scientific and practical significance and requires further study.<\/jats:p>","DOI":"10.21320\/2500-2139-2016-9-3-296-301","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T13:55:28Z","timestamp":1474293328000},"page":"296-301","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Significance of Immunophenotyping of Bone Marrow Cells in Multiple Myeloma","\u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u0437\u043d\u0430\u0447\u0435\u043d\u0438\u0435 \u0438\u043c\u043c\u0443\u043d\u043e\u0444\u0435\u043d\u043e\u0442\u0438\u043f\u0438\u0440\u043e\u0432\u0430\u043d\u0438\u044f \u043a\u043b\u0435\u0442\u043e\u043a \u043a\u043e\u0441\u0442\u043d\u043e\u0433\u043e \u043c\u043e\u0437\u0433\u0430 \u043f\u0440\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u0435"],"prefix":"10.21320","volume":"9","author":[{"given":"Oksana Yur\u2019evna","family":"Yakimovich","sequence":"first","affiliation":[{"name":"N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041a\u0430\u0448\u0438\u0440\u0441\u043a\u043e\u0435 \u0448., \u0434. 24, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 115478"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. M.","family":"Votyakova","sequence":"additional","affiliation":[{"name":"N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041a\u0430\u0448\u0438\u0440\u0441\u043a\u043e\u0435 \u0448., \u0434. 24, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 115478"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. V.","family":"Lyubimova","sequence":"additional","affiliation":[{"name":"N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041a\u0430\u0448\u0438\u0440\u0441\u043a\u043e\u0435 \u0448., \u0434. 24, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 115478"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. N.","family":"Tupitsyn","sequence":"additional","affiliation":[{"name":"N.N. Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478"},{"name":"\u0424\u0413\u0411\u0423 \u00ab\u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u043e\u043d\u043a\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u043d\u0430\u0443\u0447\u043d\u044b\u0439 \u0446\u0435\u043d\u0442\u0440 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430\u00bb \u041c\u0438\u043d\u0437\u0434\u0440\u0430\u0432\u0430 \u0420\u043e\u0441\u0441\u0438\u0438, \u041a\u0430\u0448\u0438\u0440\u0441\u043a\u043e\u0435 \u0448., \u0434. 24, \u041c\u043e\u0441\u043a\u0432\u0430, \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0430\u044f \u0424\u0435\u0434\u0435\u0440\u0430\u0446\u0438\u044f, 115478"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8834","published-online":{"date-parts":[[2016,7,1]]},"reference":[{"key":"17718","unstructured":"\u0417\u0443\u0435\u0432\u0430 \u0415.\u0415., \u0420\u0443\u0441\u0430\u043d\u043e\u0432\u0430 \u0415.\u0411., \u041a\u0443\u0440\u0442\u043e\u0432\u0430 \u0410.\u0412. \u0414\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b \u0438 \u043c\u043e\u043d\u0438\u0442\u043e\u0440\u0438\u043d\u0433 \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u0438 \u0442\u0435\u0440\u0430\u043f\u0438\u0438. \u0418\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u044f \u0433\u0435\u043c\u043e\u043f\u043e\u044d\u0437\u0430. 2008;5(2):44\u201356."},{"key":"17719","unstructured":"[Zueva EE, Rusanova EB, Kurtova AV. Diagnosis of multiple myeloma and treatment efficacy monitoring. Immunologiya gemopoeza. 2008;5(2):44\u201356. (In Russ)]"},{"key":"17720","unstructured":"Bataille R, Jero G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of \u201cmany and multiple myelomas\u201d and of new targets for myeloma therapy. Haematologica. 2006;91(9):1234\u201340."},{"key":"17721","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404815"},{"key":"17722","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20523"},{"key":"17723","doi-asserted-by":"publisher","DOI":"10.1385\/1-59259-916-8:5"},{"key":"17724","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1489"},{"key":"17725","unstructured":"Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152(6):1655\u201365."},{"key":"17726","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"17727","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0297"},{"key":"17728","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080"},{"key":"17729","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4700"},{"key":"17730","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1853"},{"key":"17731","unstructured":"Sezer O, Heider U, Zavrski I, Possinger K. Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells. Haematologica. 2001;86(8):837\u201343."},{"key":"17732","unstructured":"Moreau P, Robillard N, Avet-Loiseau H, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica. 2004;89(5):547\u201351."},{"key":"17733","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401211"},{"key":"17734","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00033-3"},{"key":"17735","unstructured":"Sarasquete ME, Garcia-Sanz R, Gonzalez D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365\u201372."},{"key":"17736","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2172"},{"key":"17737","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403948"},{"key":"17738","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0963"},{"key":"17739","unstructured":"Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol. 2000;27(5):598\u2013613."},{"key":"17740","unstructured":"\u0422\u0443\u043f\u0438\u0446\u044b\u043d \u041d.\u041d. \u0418\u043c\u043c\u0443\u043d\u043e\u043b\u043e\u0433\u0438\u044f \u043a\u043b\u0435\u0442\u043e\u043a \u043a\u0440\u043e\u0432\u0438. \u0412 \u043a\u043d.: \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. \u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0435 \u0440\u0443\u043a\u043e\u0432\u043e\u0434\u0441\u0442\u0432\u043e. \u041f\u043e\u0434 \u0440\u0435\u0434. \u041e.\u0410. \u0420\u0443\u043a\u0430\u0432\u0438\u0446\u044b\u043d\u0430. \u041c.: \u0413\u042d\u041e\u0422\u0410\u0420-\u041c\u0435\u0434\u0438\u0430, 2015. \u0421. 70\u20138."},{"key":"17741","unstructured":"[Tupitsyn NN. Blood cell immunology. In: Rukavitsyn OA, ed. Gematologiya. Natsional\u2019noe rukovodstvo. (Hematology. National guidelines.) Moscow: GEOTAR-Media Publ.; 2015. pp. 70\u20138. (In Russ)]"},{"key":"17742","unstructured":"\u041c\u0435\u043d\u0434\u0435\u043b\u0435\u0435\u0432\u0430 \u041b.\u041f., \u0412\u043e\u0442\u044f\u043a\u043e\u0432\u0430 \u041e.\u041c., \u041f\u043e\u043a\u0440\u043e\u0432\u0441\u043a\u0430\u044f \u041e.\u0421. \u0438 \u0434\u0440. \u041d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u044b\u0435 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438 \u043f\u043e \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0435 \u0438 \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. \u0413\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f \u0438 \u0442\u0440\u0430\u043d\u0441\u0444\u0443\u0437\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2014;59(\u043f\u0440\u0438\u043b\u043e\u0436\u0435\u043d\u0438\u0435 3):1\u201337."},{"key":"17743","unstructured":"[Mendeleeva LP, Votyakova OM, Pokrovskaya OS, et al. National clinical guidelines for diagnosis and treatment of multiple myeloma. Gematologiya i transfuziologiya. 2014;59(Suppl. 3):1\u201337. (In Russ)]"},{"key":"17744","unstructured":"Lin \u0420. \u041f\u043b\u0430\u0437\u043c\u043e\u043a\u043b\u0435\u0442\u043e\u0447\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430. \u041f\u0440\u043e\u0433\u0440\u0435\u0441\u0441 \u0432 \u043b\u0435\u0447\u0435\u043d\u0438\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b. Best Clin Pract, \u0440\u0443\u0441\u0441\u043a\u043e\u0435 \u0438\u0437\u0434\u0430\u043d\u0438\u0435. 2009;2:11\u20136."},{"key":"17745","unstructured":"[Lin P. Plasma cell myeloma. Progress in treatment of multiple myeloma. Best Clin Pract, Russian edition. 2009;2:11\u20136 (In Russ)]"},{"key":"17746","unstructured":"\u0412\u043e\u0442\u044f\u043a\u043e\u0432\u0430 \u041e.\u041c., \u041b\u044e\u0431\u0438\u043c\u043e\u0432\u0430 \u041d.\u0412., \u0422\u0443\u0440\u043a\u043e \u0422.\u0410. \u0438 \u0434\u0440. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0435 \u0437\u043d\u0430\u0447\u0435\u043d\u0438\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u044f \u0441\u0432\u043e\u0431\u043e\u0434\u043d\u044b\u0445 \u043b\u0435\u0433\u043a\u0438\u0445 \u0446\u0435\u043f\u0435\u0439 \u0438\u043c\u043c\u0443\u043d\u043e\u0433\u043b\u043e\u0431\u0443\u043b\u0438\u043d\u043e\u0432 \u043f\u0440\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u0435. \u0412\u0435\u0441\u0442\u043d\u0438\u043a \u0420\u041e\u041d\u0426 \u0438\u043c. \u041d.\u041d. \u0411\u043b\u043e\u0445\u0438\u043d\u0430 \u0420\u0410\u041c\u041d. 2010;5(4):16\u201320."},{"key":"17747","unstructured":"[Votyakova OM, Lyubimova NV, Turko TA, et al. Clinical implication of immunoglobulin free light chains study in patients with multiple myeloma. Vestnik RONTs im. N.N. Blokhina RAMN. 2010;5(4):16\u201320. (In Russ)]"}],"container-title":["Clinical Oncohematology"],"original-title":[],"link":[{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/501\/463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/download\/501\/463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T11:25:58Z","timestamp":1764501958000},"score":1,"resource":{"primary":{"URL":"https:\/\/bloodjournal.ru\/index.php\/coh\/article\/view\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.21320\/2500-2139-2016-9-3-296-301","relation":{},"ISSN":["2500-2139","1997-6933"],"issn-type":[{"type":"electronic","value":"2500-2139"},{"type":"print","value":"1997-6933"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}